ASCO shared a post on X:
“New guidance outlines when to utilize ctDNA testing over tissue biopsy—including patient risk mitigation, clinical timeframes, and regulatory requirements. Plus, the next steps for negative or inconclusive results are important.”
To which Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, added:
“New ASCO Guidelines on ctDNA testing Highlighting than when results are negative, tissue biopsy should be performed.”
Title: Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline
Authors: Christina M. Lockwood, Hans J. Messersmith, Annette S. Kim, Padma Sheila Rajagopal, Umang Swami, Rena Xian, Dara Aisner, Maria E. Arcila, Florence Kurttila, Christine M. Lovly, Jason D. Merker, Kanika G. Nair, Atara Isaiah Ntekim, Melanie Anne Sheen, Apostolia Maria Tsimberidou, Nicholas C. Turner and Stacy W. Gray
Other articles featuring ASCO and Estela Rodriguez on OncoDaily.
